Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

01:57 EDT 20th September 2014 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 28,000+

Friday 19th September 2014

Feedback requested on the use of Lyrica/pregabalin for an MEA leaflet | 19 September 2014

Our medical adviser, Dr Charles Shepherd, writes: I am in the process of preparing a new MEA Management File on the prescription-only pain-killing drug called Lyrica/pregabalin. I would be interested...

Feedback requested for an MEA leaflet on the use of Lyrica/pregabalin | 19 September 2014

Our medical adviser, Dr Charles Shepherd, writes: I am in the process of preparing a new MEA Management File on the prescription-only pain-killing drug called Lyrica/pregabalin. I would be interested...

September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month!

NEW YORK, Sept. 19, 2014 /PRNewswire-USNewswire/ -- An entire month is dedicated to one of the most common forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease affecting the arms, hands, feet and legs, causing extreme muscle atrophy, weakness, and foot and hand deformities. CMT affects 1 in 2,500 in the US and millions worldwid...

Pioneer Human Services Promotes Employers' Role in Addiction Recovery in the Workplace

SEATTLE, Sept. 19, 2014 /PRNewswire/ -- This September marks the 25th anniversary of National Recovery Month, an annual observance that celebrates recovery and encourages us all to take action to promote the availability of effective prevention, treatment and recovery services for those in need. As responsible citizens – employers, co-workers, neighbors and friends – we need to re...

OncoTherapy Network Highlights National Blood Cancer Awareness Month

NORWALK, Conn., Sept. 19, 2014 /PRNewswire/ -- UBM Medica US announces that  OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest news on blood cancer research and treatment.  Every September, ...

European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

-- First-in-Class Oral Treatment for Two Incurable Blood Cancers -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia (CLL) and follicular lymphoma ...

Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems

CORAL SPRINGS, Florida, September 19, 2014 /PRNewswire/ -- Biotech companies make announcements illustrating significant progress in medical technology, development of emerging drug systems and advanced Laboratory Instrumentation. Companies in focus today are: (OTC: PBIO), Benton, Dickinson and Company (NYSE: BDX), Thermo Fisher Scientific Inc. (NYSE: TMO), Regado Biosciences Inc. (NASDAQ: RGDO),...

Purina Expands Claims Of False Advertising Against Blue Buffalo To Include Pet Treats And Cat Litter

ST. LOUIS, Sept. 19, 2014 /PRNewswire/ -- Amid continued questions about the honesty of Blue Buffalo's advertising practices, Nestle Purina PetCare Company (Purina) last night filed an amended complaint in its false advertising lawsuit against the company, alleging additional false advertising in the marketing of Blue Buffalo's pet food, treats and cat litter. In a follow-up to Purin...

Pegfilgrastim biosimilar approved in South Korea

South Korean biologicals company, Green Cross, announced on 18 August 2014 that it had received marketing authorization from South Korea’s Ministry of Food and Drug Safety for its pegfilgrastim biosimilar Neulapeg.

India caps prices of 36 more drugs: government source

MUMBAI (Reuters) - India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority said on Frida...

Spectrum out-licenses rights for China to CASI Pharmaceuticals for three of its drugs

Spectrum Pharmaceuticals (SPPI) and CASI Pharmaceuticals have signed license agreements whereby CASI has been granted exclusive rights to two of Spectrum Pharmaceuticals’ commercial oncology drugs, Zevalin (ibritumomab tiuxetan) Injection for intra...

MYOS inks deal with HMT to conduct clinical metabolomic trial in subjects using fortetropin

MYOS Corporation, an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has entered into a research agreement with Human Metabolome Tec...

FDA approvals for generic AIDs and testosterone drugs

The US Food and Drug Administration (FDA) has approved generic versions of drugs to treat appetite loss in AIDs patients and a testosterone gel treatment for men.

Patient access to rituximab in emerging markets

A Pfizer-sponsored study looking at access to the oncology treatment rituximab has revealed that use of this important drug would increase across all therapy types and markets if a biosimilar was available. A rituximab biosimilar would have the great...

India caps prices of 36 more drugs -govt source

MUMBAI, Sept 19 (Reuters) - India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority said...

Gilead Emerging Market Agreement: Huge Win For Patients, Non-Event For Investors.

By Small Pharma Analyst:Over the past several months Gilead (NASDAQ:GILD) has been in discussion with Indian generic drug companies and the government to license Sovaldi for generic manufacture and distribution for low-income nations. On Sep 15, the agreement was announced - Gilead will provide a non-exclusive license to 7 Indian drug companies to manufacture and distribute Sovaldi and ledipasvir ...

FDA releases updated proposals to improve food safety and help prevent foodborne illness in response to public comments

Based on extensive outreach and public comment, the U.S. Food and Drug Administration today proposed revisions to four proposed rules designed to help prevent food-borne illness. When finalized, the proposed rules will implement portions of the FDA F...

Drug design: Guidelines for macrocycle drug design

Navidea's Lymphoseek cancer drug gets FDA orphan drug status

The US Food and Drug Administration (FDA) has granted orphan drug designation for Navidea Biopharmaceuticals' Lymphoseek (technetium Tc 99m tilmanocept) Injection for use in sentinel lymph node detection in patients with cancer of the head and neck.

New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy

MINNEAPOLIS and ORLANDO, Fla., Sept. 19, 2014 /PRNewswire/ -- The body of published data supporting Inspire therapy continues to grow, with the publication of two papers this past week.  The first paper published on-line in Otolaryngology – Head and Neck Surgery, finds that withholding Inspire therapy causes a worsening of both objective and subjective measures of sleep disordered ...

Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting

SAN FRANCISCO, Sept. 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist molecules. The preclinical research candidates were created using Nektar's small molecule polymer medicinal chemistry pla...

HelpRx.info Now Providing Discounts on All Common High Blood Pressure Medications

HelpRx.info, the leading provider of free prescription discounts, now offers discounts on all common high blood pressure medications. New York, NY (PRWEB) September 19, 2014 Script Relief, operator of HelpRx.info, now offers free Rx discounts on all commonly prescribed high blood pressure medications. HelpRx.info is the leading provider of free online drug coupons and has saved its users over $60...

It Takes Less Than 15 Minutes To Buy VVUS Shares!

By Rx Stocks:The FDA has approved new labeling for Stendra for use in as little as 15 minutes. Moreover, the marketing partner, Auxilium Pharmacueticals Inc. (NASDAQ:AUXL), just recieved a takeover bid from Endo International (NASDAQ:ENDP). Vivus Pharmaceuticals (NASDAQ:VVUS) shares have fallen dramatically since approval of Qsymia,

Lpath, Inc. Announces $12.5 Million Registered Direct Offering

SAN DIEGO, Sept. 19, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today that it has entered into definitive agreements to sell 3,605,042 registered shares of common stock and 3,605,042 unregistered warrants in a registered direct offering.  The combined purchase price for one registered share of common stock and ...

Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System

SOUTH EASTON, Mass., Sept. 19, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced it has received and approved all parts required to build nine high throughput Barozyme HT48 instruments and has begun to manufacture the new PCT-based instrument system.  The Company believes the first instrument will be ready for shipment by mid-October a...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks